strong highlight ms stabil pipelin
updat forecast estim jul
busi strategi outlook
think specialty-market-focus drug portfolio
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
extend oncolog
strategi root merger ms
drug avonex idec cancer drug rituxan rituxan market
penetr high patent unit state
deriv profit share roch expir howev
think subcutan rituxan well novel antibodi gazyva
allow
revenu avonex
longer-act plegridi gener billion annual sale
remain lead ms interferon drug acquir full right
ms antibodi tysabri billion annual sale
partner howev price power demand
inject ms portfolio slightli erod gener
version teva copaxon launch novel high-efficaci
drug reach market
oral ms drug tecfidera strong launch continu show
solid safeti efficaci data howev continu scrutini
formul patent revok europ
ipr decis valid led us assum
gener entri think vumer licens
could improv gi toler head-to-head data
tecfidera expect like
partial off-set assum total oral ms drug sale
declin howev see signific
royalti roch novel high-efficaci drug ocrevu approv
 europ help off-set pressur
ms franchis
outsid ms strong human genet valid
neurolog pipelin creat potenti off-set ms pressur spinal
muscular atrophi drug spinraza partner ioni reach
billion sale although novarti gene therapi
zolgensma approv may follow aducanumab
failur alzheim think market underestim
pipelin includ continu partnership
ioni drug candid treat condit includ stroke
parkinson pain al
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
idec merg combin forc market
multipl sclerosi drug avonex idec cancer drug rituxan today
rituxan next-gener antibodi gazyva market via
collabor roch also market novel ms drug tysabri
tecfidera japan ms portfolio co-promot eisai
hemophilia therapi eloct alprolix partner sobi spun
part bioverativ sever drug candid
phase trial neurolog neurodegen diseas
launch spinraza partner ioni
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong highlight ms stabil pipelin
report strong result second quarter
rais guidanc full year slightli
increas fair valu estim per share
account recent share repurchas price
significantli fair valu estim lower tax rate
guidanc stronger perform model
ms franchis driven tecfidera
royalti revenu roch ocrevu advanc
pipelin sever potenti driver exclud
model includ lupu pain alzheim program
think share look under-valued recent price
howev caution signific near-term
uncertainti surround spinraza potenti declin
face new competit novarti sma gene therapi
zolgensma approv end may well
tecfidera patent litig like decis
valid key patent earli overal ms
franchis solid strategi expand adjac area
like neuromuscular movement disord well
immunolog ophthalmolog contribut wide
despit expect overhang tecfidera spinraza
uncertainti see potenti posit catalyst
remaind expect immin data
head-to-head studi vumer versu tecfidera
could give better case initi new patient
vumer longer solid ip protect
tecfidera drug show improv gastrointestin
toler current assum howev tecfidera
sale tecfidera vumer billion
well consensu estim also expect first
key tau data supranuclear palsi mid-stag data
lupu drug later year model lupu
sale given prior failur mix data anoth
compound develop ucb model
rel conserv sale psp program rise
high million year model
turn headwind expect biosimilar rituxan begin
weigh profit share cancer drug
second half spinraza growth begin
dip zolgensma get better reimburs access
 model gradual eros spinraza begin
zolgensma access improv label
expand includ older patient zolgensma current
approv patient age expect
pipelin progress acceler data
begin roll parkinson drug candid
nightstar gene therapi program nsr-
rpgr follow data al drug tofersen
rais fair valu estim per
share account recent share repurchas
price significantli fair valu estim lower tax
rate guidanc stronger perform
model ms franchis
spinraza nusinersen think sale peak
billion assum sale begin declin rather
plateau new patient treat spinraza
patient could opt either compet gene therapi
novarti small-molecul therapi roche/ptc
think combin global sale avonex plegridi
continu fall high-single-digit declin annual
new competit expect tysabri declin
billion billion end
forecast jcv-posit patient switch
hit nearli billion assum see
roughli global sale assum gener
tecfidera off-set total
fumar revenu launch vumer
howev base case assum total fumar sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rel
inelast portfolio ms
treatment tecfidera may see gener competit earli
alzheim drug aducanumab
longer model demonstr high-risk natur
pipelin target base-cas
scenario expect tecfidera/vumer sale fall
around billion also assum tysabri sale
peak billion think new patient add
patient test seroneg jc viru antibodi
 price power may abl counter impact
discontinu seroposit patient new
altern regimen ocrevu long run
scenario think oper margin remain
bull-cas scenario -- valu per
share -- tysabri sale stay flat explicit
forecast period also assum tecfidera
vumer becom domin player ms market
allow secur billion annual sale
assum tecfidera patent hold
vumer see signific gi benefit tecfidera
bear-cas scenario valu per share
assum heavi discontinu new competit
threat weigh tysabri sale global tysabri sale
declin million also forecast minim
 sale tecfidera/vumer assum
gener tecfidera gi benefit vumer
achiev strong profit success
three market product field oncolog
neuroimmunolog introduct tecfidera secur
firm domin share ms market think
barrier entri high potenti biosimilar
product strong strategi
maintain leadership ms price power
strong patient need novel therapi high
pipelin particularli product factor
fall roughli billion billion
assum probabl approv opicinumab
sale billion year forecast
approv although includ alzheim therapi
model continu includ probabl
approv tau antibodi supranuclear palsi
see oper margin
remain rel flat model cost spinraza
profit-shar partner ioni vumer royalti
payment counter ocrevu royalti
overal think top-lin growth averag
neg share-repurchas activ
enabl firm achiev averag earn per
share growth period
still rate systemat risk surround share
averag use cost equiti
assumpt align capit cost assumpt
return equiti investor like demand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
contribut firm wide moat return invest
capit think averag mid-teen
explicit forecast period easili exceed
estim cost capit
rituxan remain standard care sever form
hematolog cancer collabor revenu receiv
partner roch boost margin
avonex lead interferon therapi ms
long-term safeti record rel conveni
tysabri achiev blockbust sale base outstand
efficaci despit rare seriou side effect think
effort target drug patient least like
experi side effect allow firm see continu
sale despit novel product cleaner safeti profil
howev expect combin sale tecfidera
vumer declin tecfidera billion
billion annual base gener tecfidera
except tecfidera current
blockbust biolog biosimilar competit
loom threat think signific manufactur
develop cost biosimilar maker expect
incur would slow eros sale product
limit number contend abil
compet price data qualiti may also issu
biosimilar first applic avonex biosimilar
reject base insuffici efficaci delay
discontinu rituxan biosimilar push
european launch tysabri like
lower-prior target biosimilar entrant given risk
monitor potenti seriou side effect certain
see moat trend stabl think
introduct new product firm grow
late-stag pipelin off-set new competit
competit price pressur ms oncolog
increas think strong efficaci oral ms therapi
biogen tecfidera novarti gilenya inject
therapi roch launch ocrevu make
less like new patient start older inject
avonex tysabri addit payer
leverag price negoti assum
abl take avonex price increas
roughli annual net basi past sever
year think futur price chang
like closer mid-single-digit increas biogen
recent launch conveni interferon therapi
plegridi littl chang trend opinion
model high-single-digit declin combin
avonex/plegridi tysabri go forward addit
report revenu cancer therapi rituxan
matur biosimilar competit draw
howev think pipelin off-set
pressur older drug roch receiv food drug
administr approv novel effect antibodi
therapi ocrevu relaps ms
compet primari progress ms
approv treatment littl off-label use
current drug add competit
landscap also benefit due roughli
royalti sale two third global
billion ms market exposur new ppm
indic biogen anti-lingo drug candid key part
ms pipelin drug could help repair myelin
sheath coat neuron give novel mechan
action potenti allow patient regain lost
function drug fail hit key endpoint
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
extend oncolog profit stream
phase studi saw encourag data
clinic respons opicinumab continu move forward
develop oncolog expect partner
subcutan rituxan also next-gener drug
gazyva launch leukemia product
superior efficaci profil rituxan recent
approv larg indol first-lin lymphoma set
individu odd approv mix bullish
novel broader neurolog rare-diseas
pipelin includ sever product high risk
spinraza launch annual price
lack treatment option rare deadli diseas
could creat billion market although
assum sale could peak around billion
spinraza begin share market novarti gene
therapi zolgensma divers pipelin follow
spinraza area includ ms next-gener fumar
vumer novel re-myelin therapi opicinumab
al follow
failur aducanumab program alzheim
expect similar fate firm amyloid antibodi
recent failur bace inhibitor
lack differenti elenbecestat reduc
enthusiasm class drug think
tau antibodi could see sale billion
approv treatment supranuclear palsi assum
probabl drug well two
tau-target therapi neurimmun ioni
develop alzheim give exposur
potenti new target diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lead billion global ms market
avonex plegridi tysabri vumer could improv
tecfidera gi side effect
receiv royalti profit share roch
ms drug ocrevu cancer therapi rituxan
neurolog portfolio outsid ms includ
spinraza therapi sever neurolog
diseas includ parkinson al alzheim
help diversifi revenu boost sale growth
oinject ms therapi avonex lost edg
lead therapi brand oral competit
gener inject launch tysabri risk
profil pml patient jc viru posit
make vulner patient switch roch
aducanumab fail march demonstr
high-risk natur neurolog pipelin
drive growth oral
competit roche/ptc gene therapi novarti
could threaten franchis
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end cash balanc billion free
cash flow billion annual help fund
futur repurchas allow firm flexibl size
futur acquisit firm cash invest
balanc sheet match similar amount debt
matur issu billion
debt help fund share-repurchas program
histor focus return excess cash
sharehold via buyback limit acquisit
collabor record strong expect tuck-in
acquisit go forward billion free cash
flow gener spent vast
major cash repurchas averag
repurchas price per share
profit depend four key blockbust
high-risk potenti high-reward pipelin
physician payer fail support gazyva use
rituxan despit strong superior data leukemia
larg lymphoma set roch could
vulner competit cheaper biosimilar rituxan
 revenu roch
collabor feed directli bottom line boost
margin plegridi like help
maintain lead interferon market expect gener
copaxon weigh sale inject ms therapi
ms portfolio enjoy tremend price
power unit state insur could begin find
way put pressur futur price increas
competitor reach market avonex plegridi
exclud nation formulari
tecfidera sale see slower growth partli due
concern case pml gastrointestin issu
oral drug celgen ozanimod pois
enter market gener version tecfidera could enter
 market success ipr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
challeng decis expect recent failur
alzheim therapi aducanumab phase trial also
demonstr high-risk natur
chosen area focu within neurolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
ft growth trea
new york mellon corp
share
fund
share
fund
scango took ceo juli longtim
execut jame mullen serv ceo
development-stag biotech year
previous spend year bayer scango help
refocu pipelin neurodegen diseas
neurology-rel indic build strong team
neurolog drug discoveri emphas small tuck-in
commerci offic toni kingsley chief doug
left scango depart
begin decis spin firm
hemophilia franchis led specul firm
sale despit turnov chief medic offic alfr
sandrock decad experi support
pipelin current ceo michael vounatso previous
chief commerci offic career
longtim director william young step
role independ chairman replac stelio
papadopoulo chairman regulu
annual meet may overal see
board well qualifi divers independ despit
long tenur sever director applaud
effort emphas restrict stock option
compens packag top execut
believ align interest sharehold howev
take-over defens author prefer stock may
work interest sharehold complex right
agreement partner roch
trigger acquir could damp
enthusiasm potenti acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong highlight ms stabil pipelin
report strong result second quarter
rais guidanc full year slightli
increas fair valu estim per share
account recent share repurchas price
significantli fair valu estim lower tax rate
guidanc stronger perform model
ms franchis driven tecfidera
royalti revenu roch ocrevu advanc
pipelin sever potenti driver exclud
model includ lupu pain alzheim program
think share look under-valued recent price
howev caution signific near-term
uncertainti surround spinraza potenti declin
face new competit novarti sma gene therapi
zolgensma approv end may well
tecfidera patent litig like decis
valid key patent earli overal ms
franchis solid strategi expand adjac area
like neuromuscular movement disord well
immunolog ophthalmolog contribut wide
despit expect overhang tecfidera spinraza
uncertainti see potenti posit catalyst
remaind expect immin data
head-to-head studi vumer versu tecfidera
could give better case initi new patient
vumer longer solid ip protect
tecfidera drug show improv gastrointestin
toler current assum howev tecfidera
sale tecfidera vumer billion
well consensu estim also expect first
key tau data supranuclear palsi mid-stag data
lupu drug later year model lupu
sale given prior failur mix data anoth
compound develop ucb model
rel conserv sale psp program rise
high million year model
turn headwind expect biosimilar rituxan begin
weigh profit share cancer drug
second half spinraza growth begin
dip zolgensma get better reimburs access
 model gradual eros spinraza begin
zolgensma access improv label
expand includ older patient zolgensma current
approv patient age expect
pipelin progress acceler data
begin roll parkinson drug candid
nightstar gene therapi program nsr-
rpgr follow data al drug tofersen
under-valued wake aducanumab failur apr
maintain fair valu estim biogen
follow strong first-quart result top-lin
growth non-gaap ep growth continu
see share significantli under-valued wake
aducanumab failur remaind year
expect revenu growth sink singl digit first-
quarter perform tailwind one-tim sale
hemophilia inventori bioverativ non-gaap ep
growth remain strong benefit end
consensu firm prospect tecfidera
assum gener entri follow ipr spinraza
assum slight declin sale begin
includ almost billion revenu
firm extens pipelin neurolog adjac
area manag expect key data
program end think provid
posit catalyst uncertainti
surround share remain high due tecfidera
ip statu impend spinraza competit think
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
resili firm ms franchis exemplifi
sustain cash flow firm ms portfolio
neurolog pipelin continu support wide moat
encourag solid growth spinraza
quarter expect continu double-digit growth
remaind novarti gene therapi zolgensma
like launch slowli second half howev
assum mid-single-digit declin spinraza
follow manag see sma
patient global market well prior estim
focus larg north america europ
assum price addit market would
significantli lower cautiou abil
penetr market substanti believ
offer upsid base case spinraza
pend nightstar acquisit net posit impact
fair valu estim counter
aducanumab failur last updat think
clinical-stag retin degener program potenti
approach billion think continu add
pipelin smaller deal firm signal
also expect continu ramp share
repurchas activ given recent share price
spent billion far share repurchas
author billion like manag
appear fight temptat make big
acquisit counter hit aducanumab failur
particularli given high number clinic program
data expect end among
potenti posit catalyst encourag
potenti vumer patent head-to-
head data versu tecfidera
nightstar data second half ionis-partn
al program data program second half
howev signific upsid also exist
establish efficaci tau progress supranuclear palsi
data second half alpha-synuclein target
parkinson data second half either two
aducanumab failur weigh fve firm
plan lower fair valu estim biogen
follow news phase trial alzheim
drug aducanumab engag emerg
discontinu due futil previous assign
drug probabl approv base strong data
smaller trial drug differenti fail
amyloid antibodi still chanc
drug could work prevent set remov
amyloid antibodi revenu forecast includ
mix data uncertain path
forward pivot trial model expect
action lower fair valu estim
also roll model incorpor pend
nightstar acquisit could modestli sway
valuat rang
continu believ neurolog portfolio
pipelin warrant wide moat rate firm
pipelin see signific progress beyond alzheim
market
pivot trial parkinson phase stroke phase
pain enter phase trigemin neuralgia
program counter expect pressur tecfidera
gener model unit state
spinraza competit novarti zolgensma track
food drug administr approv type spinal
muscular atrophi may
see catalyst vumer ms approv
head-to-head data gastrointestin toler
versu tecfidera tysabri epilepsi data tau antibodi
data progress supranuclear palsi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
novarti look pois launch sma gene therapi
zolgensma year think spinraza
continu grow zolgensma like label
type infant midteen spinraza growth
line forecast assum averag annual
declin midsingl digit spinraza follow
due zolgensma roch phase oral drug risdiplam
biggest catalyst remain phase aducanumab
data earli continu assign probabl
success also see catalyst
ms approv head-to-head data
epilepsi data tau antibodi
progress supranuclear palsi detail analysi
top-lin growth prospect pipelin candid
pleas see healthcar observ annual drug pipelin
report moat remain secur innov counter
price gener headwind acceler
detail analysi top-lin growth prospect
pipelin candid pleas see healthcar observ
annual drug pipelin report moat remain secur
innov counter price gener headwind
franchis stabl pipelin expand jan
report result broadli line
top- bottom-lin expect multipl
sclerosi sale hold slightli better
expect slightli less growth biosimilar
spinraza model model
higher spinraza ms sale well lower
expens top- bottom-lin estim line
manag guidanc howev boost
sg expens long run account multipl
potenti launch neurolog led aducanumab
alzheim maintain fair
valu estim continu believ
neurolog portfolio pipelin warrant wide moat rate
share look under-valued partli due investor
concern outcom phase trial
aducanumab think share look under-valued
regardless aducanumab trial outcom
pipelin see signific progress beyond alzheim
market like ms two midstag remyelin agent
phase pain enter phase trigemin
ms franchis see improv stabil
opinion outsid like inventori drawdown
first quarter think quarter-over-quart growth
remain stabl drain tysabri roch ocrevu
appear lessen delay celgen ozanimod
give tecfidera vumer anoth year rel
minim chang oral ms drug landscap
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
